Up next

CDMO Outlook: Small Molecules—What Lies Ahead?

Sponsored by Vetter

Brian Scanlan, Managing
Partner, Freedom Bioscience Partners

As the industry reaches the mid-point in 2026, how are CDMOs of small-molecule drugs faring? The larger scale CDMOs with late-phase and/or commercial-scale capabilities are faring well while smaller and mid-sized CDMOs specializing in early-stage development and clinical-scale capabilities are facing some headwinds from more challenging trends in biotech financing, but opportunities lie ahead. Brian Scanlan, Managing Partner, Freedom Bioscience Partners, a strategic advisory firm to CROs, CDMOs, and investors, provides the latest insights.

Each episode of the Production to Prescription podcast is housed on the DCAT Value Chain Insights website and also delivered through DCAT Value Chain Insights weekly email digest. Not a subscriber? Click here to subscribe to DCAT Value Chain Insights, or get each episode through: 

For a full list of the 2026 podcast episode schedule, click here.

You May Also Like

Beyond ADCs: Next-Generation Drug Conjugates

By
Sponsored by Lonza AG Next-generation complex conjugates, such as peptide conjugates, radioconjugates, ligand-conjugated antisense medicines, and small-molecule drug conjugates, are expected to outpace growth comparative to antibody drug conjugates (ADCs),…

New Excipient Products: Are They Coming?

By
Innovation in excipients is important to optimize a drug formulation, but there are barriers to innovation, including regulatory barriers, which excipient manufacturers and users are seeking to address. Providing the…

Pipeline Potential: Small-Molecule Drugs

By
New drug classes–proteolysis-targeting chimeras (PROTACs) and molecular glue degraders–are potentially a new source of product innovation for small-molecule drugs in their ability to reach previously “undruggable” drug targets. There have…

A CDMO Roundtable: The Making of a Molecule: Peptide Synthesis

By
The blockbuster success of the GLP-1 agonists and related drugs has renewed interest in peptide-based drugs, but how is the manufacturing technology evolving? In a CDMO roundtable, industry experts share…